Guggenheim analyst Louise Chen reiterated a Buy rating and $230 price target on Perrigo Co. (NYSE: PRGO) ahead of Friday, saying the stock could offer more upside than the Mylan (NYSE: MYL) deal. Chen commented, "We don't …
However, the damage had already been done… United stock took a hit, as shares of UAL slipped more ... Perrigo Co. American pharmaceuticals company Perrigo …
Now that that’s out of the way, we’re going to analyze the latest info surrounding Perrigo Company (NYSE:PRGO). In …
Teva’s stock rally has helped give a boost to rival generic drugmakers. Shares of Mylan N.V MYL, +0.64% climbed 2.9% and Perrigo Co. PLC PRGO, +0.13% ran up 2.8%. Over the past thee months, Teva’s stock has still shed 39%, while …
Should you or shouldn’t you go anywhere near VRX stock right now? For the first seven months of ... information to Martoma about a 2008 Alzheimer's drug trial. Perrigo (PRGO) gains an FDA consent for the OTC version of …
US-based healthcare products company Perrigo Co. (PRGO) has agreed to acquire Irish biotechnology firm Elan Corp. Plc. (ELN) in a cash and stock transaction valued at about $8.6 billion. Elan, which recently refused to be acquired by …
Safirstein Metcalf LLP announces that a class action has been filed the United States District Court for the District of …
Perrigo Company plc Ordinary Shares (NYSE: PRGO) is considering the potential sale of its ... Expressing concern regarding the weak near-term outlook for Perrigo, Kilstein stated that “the Tysabri sale is unwise given the drug’s …
Though Mylan offered $205 per share, $75 of which was in cash, then-CEO of Perrigo Joe Papa defended his company from buy-out, telling investors and the public that he expected the shares of Perrigo stock to be worth more than that by …
Perrigo Company plc PRGO is scheduled to report third-quarter 2016 results on Nov 10, before the opening bell. Perrigo has a mixed track record with the company beating earnings expectations on two occasions and missing the same in …